In vitro activity of sparfloxacin compared with those of five other quinolones
- 1 March 1992
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 36 (3) , 558-565
- https://doi.org/10.1128/aac.36.3.558
Abstract
The in vitro activity of sparfloxacin, a new difluorinated quinolone, was evaluated against 857 gram-positive and gram-negative clinical isolates and compared with those of ciprofloxacin, norfloxacin, ofloxacin, fleroxacin, and lomefloxacin. The MIC of sparfloxacin for 90% of the members of the family Enterobacteriaceae tested was 0.5 microgram/ml (range, 0.06 to 4.0 micrograms/ml); only for members of the genera Serratia, Citrobacter, and Providencia were MICs above 1 microgram/ml. Some 90% of Pseudomonas aeruginosa isolates were inhibited by 8 micrograms of the drug per ml. The MICs for 90% of Staphylococcus spp. and Enterococcus faecalis were 0.12 and 2 micrograms/ml, respectively. All (100%) Streptococcus pneumoniae strains were inhibited by 0.5 microgram/ml. The inoculum size had little effect on either the MIC or the MBC of sparfloxacin. An increase in the magnesium concentration from 1.1 to 8.4 mM increased the MIC between 2 and 10 times, depending on the genus tested. Sparfloxacin was less active at pH 5. The antibacterial activity of sparfloxacin against gram-positive bacteria was generally higher than those of the quinolones with which it was compared; against Streptococcus pneumoniae, sparfloxacin was four- and eightfold more active than ofloxacin and ciprofloxacin, respectively. The activity of sparfloxacin against gram-negative rods was generally comparable to that of ciprofloxacin except against Enterobacter and Acinetobacter spp., Pseudomonas cepacia, Xanthomonas maltophilia, and Alcaligenes and Flavobacterium spp., against which sparfloxacin was the most active quinolone.Keywords
This publication has 15 references indexed in Scilit:
- In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacinAntimicrobial Agents and Chemotherapy, 1990
- Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogensAntimicrobial Agents and Chemotherapy, 1990
- Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacinAntimicrobial Agents and Chemotherapy, 1990
- In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1990
- In vitro studies of ciprofloxacin and survey of resistance patterns in current isolatesDiagnostic Microbiology and Infectious Disease, 1990
- Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolatesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Pharmacokinetics of a novel quinolone, AT-4140, in animalsAntimicrobial Agents and Chemotherapy, 1990
- In vitro activity of AT-4140 against clinical bacterial isolatesAntimicrobial Agents and Chemotherapy, 1989
- In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinoloneAntimicrobial Agents and Chemotherapy, 1989
- Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivativeAntimicrobial Agents and Chemotherapy, 1988